- Home
- BEBE vs AARD Comparison
BEBE vs AARD Comparison
Compare BEBE & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$6.82
Company Overview
Basic Information| Metric | BEBE | AARD |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.0M | 165.8M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BEBE | AARD |
|---|---|---|
| Price | $9.99 | $6.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 16.6K | ★ 116.5K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.81 | $3.35 |
| 52 Week High | $10.00 | $17.94 |
Technical Indicators
Market Signals| Indicator | BEBE | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 52.74 |
| Support Level | $9.97 | $4.99 |
| Resistance Level | $10.00 | $8.02 |
| Average True Range (ATR) | 0.00 | 0.83 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 71.43 | 44.92 |
Price Performance
Historical Comparison BEBE
AARD
About BEBE TGE Value Creative Solutions Corp Class A Ordinary Shares
TGE Value Creative Solutions Corp is a blank check company.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.